MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Cost of Revenue 2011-2026 | OPK
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 495 M | 545 M | 716 M | - | - | - | - | - | 564 M | 193 M | 48 M | 48.9 M | 27.9 M | 17.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 716 M | 17.2 M | 295 M |
Quarterly Cost of Revenue OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107 M | 107 M | - | 131 M | 132 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.4 M | 10.3 M | - | 11.1 M | 12.6 M | 12.4 M | - | 12 M | 13.1 M | 11.8 M | - | 7.49 M | 6.55 M | 4.99 M | - | 4.02 M | 4.89 M | 4.18 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 4.02 M | 33.7 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
2.91 B | $ 121.02 | 1.7 % | $ 36.8 B |  USA |
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 22.3 | -5.27 % | $ 234 M |  China |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 28.14 | 2.07 % | $ 782 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 14.14 | 2.56 % | $ 428 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
IDEXX Laboratories
IDXX
|
1.64 B | $ 650.0 | 2.28 % | $ 52.3 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 129.59 | 0.02 % | $ 20.6 B | USA |
 |
BioNano Genomics
BNGO
|
30.4 M | $ 1.14 | 1.88 % | $ 1.45 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 208.63 | 0.13 % | $ 23.2 B | USA |
 |
Danaher Corporation
DHR
|
10 B | $ 205.32 | 0.63 % | $ 146 B | USA |
 |
Organovo Holdings
ONVO
|
5 K | - | -2.3 % | $ 19.4 M | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | $ 103.51 | 0.13 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
184 M | $ 8.42 | -3.66 % | $ 527 M | USA |
 |
DarioHealth Corp.
DRIO
|
14.4 M | $ 9.65 | -6.26 % | $ 274 M | Israel |
 |
DexCom
DXCM
|
1.86 B | $ 73.39 | 0.42 % | $ 28.6 B | USA |
 |
PerkinElmer
PKI
|
1.44 B | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
13.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
Quotient Limited
QTNT
|
20.1 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 110.81 | 1.94 % | $ 9.14 B |  Irlanda |
 |
Renalytix AI plc
RNLX
|
2.13 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 19.28 | 2.56 % | $ 1.03 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 281.11 | -0.69 % | $ 23.4 B | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 77.74 | -1.4 % | $ 5.25 B | USA |
 |
Guardant Health
GH
|
349 M | $ 93.95 | 0.7 % | $ 11.8 B | USA |
 |
IQVIA Holdings
IQV
|
10.9 B | $ 177.49 | 2.0 % | $ 30.5 B | USA |
 |
Brainsway Ltd.
BWAY
|
6.6 M | $ 12.53 | 8.11 % | $ 99.4 M | Israel |
 |
Co-Diagnostics
CODX
|
4.18 M | - | - | $ 79.8 M | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 5.35 | 1.04 % | $ 495 M | USA |